Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H4 antibody drug conjugate BG-C9074

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to an as of yet unknown cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-B7-H4 ADC BG-C9074, the anti-B7-H4 monoclonal antibody moiety targets and binds to B7-H4 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent exerts an as of yet unknown mechanism of action (MoA) causing apoptosis in B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and tumor-associated macrophages (TAMs). It negatively regulates T-cell immune responses.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC BG-C9074
anti-B7-H4 ADC BG-C9074
Code name:BG C9074
BG-C9074
BGC9074
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search